Aims. The aim of this study was to identify potential driver genetic alterations in a dedifferentiated liposarcoma (DDLPS) with rhabdomyosarcomatous differentiation. Methods and Results. A 24-year-old female underwent resection of an abdominal mass, which on a previous biopsy demonstrated rhabdomyosarcomatous differentiation concerning for embryonal rhabdomyosarcoma. Histologically the resected tumor displayed a high-grade sarcoma with rhabdomyosarcomatous differentiation in the background of well-differentiated liposarcoma consistent with DDLPS. Fluorescence in situ hybridization confirmed MDM2 amplification, as did array-based copy number profiling. Whole-exome sequencing revealed a somatic FGFR1 hotspot mutation and RNA sequencing an LMNB2-MAP2K6 fusion only within the dedifferentiated component. Conclusions. This study represents an in-depth examination of a rare DDLPS with rhabdomyosarcomatous differentiation in a young individual. Additionally, it is also instructive of a potential pitfall when assessing for MDM2 amplification in small biopsies. Despite exhaustive analysis, mutation and gene copy number analysis did not identify any molecular events that would underlie the rhabdomyoblastic differentiation. Our understanding of what causes some tumors to dedifferentiate as well as undergo divergent differentiation is limited, and larger studies are needed.
EvansHL.Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979;3:507-523.
2.
DalalKMKattanMWAntonescuCRBrennanMFSingerS.Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381-391.
3.
CinPDKoolsPSciotR, et al. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet. 1993;68:85-90.
4.
CoindreJMPédeutourFAuriasA.Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010;456:167-179.
5.
Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950-965.e28.
EvansHLKhuranaKKKempBLAyalaAG.Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol. 1994;18:1150-1157.
8.
BinhMBGuillouLHosteinI, et al. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol. 2007;31:1557-1566.
9.
LokkaSScheelAHDangoS, et al. Challenging dedifferentiated liposarcoma identified by MDM2-amplification, a report of two cases. BMC Clin Pathol. 2014;14:36.
10.
GronchiAColliniPMiceliR, et al. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. Am J Surg Pathol. 2015;39:383-393.
11.
FletcherCDMBridgeJAHogendoornPMertensF. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed.Lyon, France: International Agency for Research on Cancer; 2013.
12.
JungHSLeffertsJATsongalisGJ.Utilization of the oncoscan microarray assay in cancer diagnostics. Appl Cancer Res. 2017;37:1.
13.
WeigeltBBiRKumarR, et al. The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. J Natl Cancer Inst. 2018;110:1030-1034.
14.
ParejaFBrandesAHBasiliT, et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun. 2018;9:3533.
15.
LiHDurbinR.Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
16.
ChangMTBhattaraiTSSchramAM, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8:174-183.
17.
CarterSCibulskisKHelmanE, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413-421.
18.
ShenRSeshanVE.FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131.
19.
ParejaFLeeJYBrownDN, et al. The genomic landscape of mucinous breast cancer [published online January 11, 2019]. J Natl Cancer Inst. doi:10.1093/jnci/djy216
20.
DobinADavisCASchlesingerF, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.
21.
LangmeadBSalzbergSL.Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357-359.
22.
ZhangJWhiteNMSchmidtHK, et al. INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Genome Res. 2016;26:108-118.
23.
HaasBJDobinAStranskyN, et al. STAR-fusion: fast and accurate fusion transcript detection from RNA-seq [published online March 24, 2017]. bioRxiv. doi:10.1101/120295
24.
WangKSinghDZengZ, et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010;38:e178.
25.
NicoriciDŞatalanMEdgrenH, et al. FusionCatcher—a tool for finding somatic fusion genes in paired-end RNA-sequencing data [published online November 19, 2014]. bioRxiv. doi:10.1101/011650
26.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
27.
ShugayMde MendíbilIOVizmanosJLNovoFJ.Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions. Bioinformatics. 2013;29:2539-2546.
28.
PiscuoglioSNgCKMurrayM, et al. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. J Pathol. 2016;238:508-518.
29.
ChibaKLorbeerFKShainAH, et al. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science. 2017;357:1416-1420.
30.
ZehirABenayedRShahRH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10 000 patients. Nat Med. 2017;23:703-713.
31.
LonganoADuGuesclinAMitchellC.Primary dedifferentiated liposarcoma of the lung with rhabdomyoblastic and chrondroblastic differentiation. Histopathology. 2015;67:923-925.
32.
SalzanoRPJrTomkiewiczZAfricanoWA.Dedifferentiated liposarcoma with features of rhabdomyosarcoma. Conn Med. 1991;55:200-202.
33.
ShimadaSIshizawaTIshizawaKKamadaKHiroseT.Dedifferentiated liposarcoma with rhabdomyoblastic differentiation. Virchows Arch. 2005;447:835-841.
34.
TalliniGErlandsonRABrennanMFWoodruffJM.Divergent myosarcomatous differentiation in retroperitoneal liposarcoma. Am J Surg Pathol. 1993;17:546-556.
35.
OkamotoSMachinamiRTanizawaTMatsumotoSLeeGHIshikawaY.Dedifferentiated liposarcoma with rhabdomyoblastic differentiation in an 8-year-old girl. Pathol Res Pract. 2010;206:191-196.
36.
FawcettTWEastmanHBMartindaleJLHolbrookNJ.Physical and functional association between GADD153 and CCAAT/enhancer-binding protein beta during cellular stress. J Biol Chem. 1996;271:14285-14289.
37.
JungHKimWKKimDH, et al. Involvement of PTP-RQ in differentiation during adipogenesis of human mesenchymal stem cells. Biochem Biophys Res Commun. 2009;383:252-257.
38.
MarianiOBrennetotCCoindreJM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11:361-374.
39.
SeoEBasu-RoyUGunaratnePH, et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep. 2013;3:2075-2087.
40.
HorvaiAEDeVriesSRoyRO’DonnellRJWaldmanF.Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-1488.
41.
ParhamDBarrF. Embryonal rhabdomyosarcoma. In: FletcherCDMBridgeJAHogendoornPCWMertensF, eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: International Agency for Research on Cancer; 2013:127-129.
42.
PaulsonVChandlerGRakhejaD, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50:397-408.
43.
HatleyMTangWGarciaMR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012;22:536-546.
44.
SinghSVinsonCGurleyCM, et al. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Surg Pathol. 2010;177:2055-2066.
45.
FowlerDMKoulovAVAlory-JostCMarksMSBalchWEKellyJW.Functional amyloid formation within mammalian tissue. PLoS Biol. 2006;4:e6.
46.
TurnerNGroseR.Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116-129.
47.
TaylorJG6thCheukATTsangPS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119:3395-3407.
48.
LiCShenYRenY, et al. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma. Hum Pathol. 2016;55:143-150.
49.
ParrayAABabaRABhatHF, et al. MKK6 is upregulated in human esophageal, stomach, and colon cancers. Cancer Invest. 2014;32:416-422.
50.
QuanVZhangBMohanL, et al. Activating structural alterations in MAPK genes are distinct genetic drivers in a unique subgroup of spitzoid neoplasms. Am J Surg Pathol. 2019;43:538-548.
51.
SoglioDBDRougemontALAbsiR, et al. SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. Hum Pathol. 2009;40:1347-1352.
52.
CockerHAHobbsSMTiffinNPritchard-JonesKPinkertonCRKellandLR.High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer. 2001;85:1746-1752.
53.
YooJParkSYKangSJShimSIKimBK.Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002;126:567-573.
54.
TosAPDMarino-EnriquezAPedeutourF, et al. Dedifferentiated liposarcoma. In: FletcherCDMBridgeJAHogendoornPCWMertensF, eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: International Agency for Research on Cancer; 2013:37-38.
55.
OgnjanovicSLinaberyAMCharbonneauBRossJA.Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009;115:4218-4226.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
